William Blair Weighs in on Amgen's Q4 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN - Free Report) - Equities research analysts at William Blair upped their Q4 2024 earnings per share estimates for Amgen in a research note issued on Tuesday, October 15th. William Blair analyst M. Phipps now forecasts that the medical research company will post earnings per share of $5.65 for the quarter, up from their previous forecast of $5.48. The consensus estimate for Amgen's current full-year earnings is $19.49 per share. William Blair also issued estimates for Amgen's Q4 2025 earnings at $4.44 EPS, FY2025 earnings at $20.03 EPS and FY2026 earnings at $18.63 EPS.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to analysts' expectations of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business's revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the business earned $5.00 EPS.

Several other equities research analysts have also recently commented on the company. Truist Financial cut Amgen from a "buy" rating to a "hold" rating and increased their price target for the company from $320.00 to $333.00 in a report on Monday. Oppenheimer reaffirmed an "outperform" rating and issued a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. Cantor Fitzgerald started coverage on Amgen in a report on Friday, September 27th. They issued an "overweight" rating and a $405.00 price target for the company. Sanford C. Bernstein started coverage on Amgen in a research note on Thursday. They set an "outperform" rating and a $380.00 target price for the company. Finally, Argus raised their target price on Amgen from $300.00 to $340.00 and gave the stock a "buy" rating in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $329.48.

Amgen Price Performance

Shares of NASDAQ:AMGN traded down $0.30 during midday trading on Thursday, hitting $321.33. The company had a trading volume of 1,635,281 shares, compared to its average volume of 2,452,432. Amgen has a twelve month low of $249.70 and a twelve month high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The stock has a market cap of $172.37 billion, a price-to-earnings ratio of 45.82, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The business's 50-day simple moving average is $326.15 and its 200-day simple moving average is $311.56.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.80%. Amgen's dividend payout ratio (DPR) is presently 128.57%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hershey Financial Advisers LLC purchased a new position in Amgen in the second quarter valued at $30,000. nVerses Capital LLC purchased a new stake in Amgen during the 2nd quarter worth about $31,000. Bbjs Financial Advisors LLC purchased a new stake in Amgen during the 2nd quarter worth about $33,000. Matrix Trust Co purchased a new stake in Amgen during the 3rd quarter worth about $36,000. Finally, FSA Wealth Management LLC lifted its holdings in Amgen by 182.0% during the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company's stock worth $40,000 after buying an additional 91 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.